ABOUT CELYAD ONCOLOGY

Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer

More Info About Celyad ONCOLOGY

Latest News

Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Celyad Oncology Announces FDA Lifts Clinical Hold of CYAD-101-002 Phase 1b Trial

Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

Celyad Oncology Announces Leadership Updates

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

Letter to Shareholders – March 2022

Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights

Discover All News

Our SCIENCE

At Celyad Oncology, we are pursuing next-generation cellular immunotherapies by applying our broad understanding of immunology, novel technology platforms and modular design approach to drug discovery.

Novel CAR T Immunotherapies

Advancing both allogeneic and autologous CAR T therapy candidates for the treatment of cancer

View Pipeline

Celyad Oncology @celyadsa ·

22 Sep

An #intellectualproperty portfolio supports future revenue streams and erects barriers to competition. IP can also be tied to a company's perceived value to investors, partners, and acquirers.

Twitter 1572979315301556225

Celyad Oncology @celyadsa ·

20 Sep

We are excited to announce that @CellisticCT is acquiring our cell therapy manufacturing facility, our first step in a renewed business model and strategy to explore additional value-adds to the company. Learn more about this announcement here: https://buff.ly/3ds52VG

Twitter 1572096471008157696

View All

Stay informed about the latest news!

Sign up FOR our newsletter

By clicking on “send”, you consent that your personal data will be processed by us in order to send you our newsletter. You have the right to access, rectify, erase your data, to restrict the processing and the right to withdraw your consent at any time. You can find more information on how we process your data in our Privacy Policy.